Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Ranbaxy stops API shipments from Indian plants
9:01 AM MST | February 26, 2014 | Deepti Ramesh
Ranbaxy Laboratories (Gurgaon, India) says that it has temporarily suspended shipping active pharmaceutical ingredients (APIs) produced at its plants at Toansa and Dewas, India. The company is currently examining processes and controls at all its API manufacturing plants and quality units, Ranbaxy says. The announcementfollows the US FDA's announcement on 23 January prohibiting Ranbaxy from manufacturing and distributing APIs from its Toansa facility for FDA-regulated drug products. API shipments from the Toansa plant to the United States were suspended on 24...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee